Drug Trial Radar · NCT07336940
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Sep 10, 2025
Primary completion
Jan 13, 2026
Study completion Jan 13, 2026
Sponsor
- Lead sponsor
- Enveda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis? * Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 once every day for 28 days * Visit the clinic weekly for 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294
Conditions
- Atopic Dermatitis (AD)
Interventions
ENV-294 CapsuleDrug
ENV-294 formulated as 200mg capsules for oral administration will be used for this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis.Time frame: From enrollment through treatment and the final study visit at approximately day 42.
- Incidence of abnormalities in clinical chemistry parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through end of study at approximately Day 42.
- To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitisTime frame: From first dose through treatment and the final study visit at approximately day 42.
- Incidence of clinically significant changes in systolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.Time frame: From first dose through treatment and the final study visit at approximately day 42.
- Incidence of clinically significant changes in heart rate (beats per minute) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit at approximately day 42.
- Incidence of abnormalities in hematology parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
- Incidence of abnormalities in coagulation parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
- Incidence of abnormalities in urinalysis parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
- Incidence of clinically significant changes in diastolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in heart rate as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in respiratory rate as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in body temperature as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in RR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in PR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
- Incidence of clinically significant changes in QRS duration (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in QT interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
- Incidence of clinically significant changes in QTc Bazett (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42)
- Incidence of clinically significant changes in QTc Fridericia (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: From enrollment through treatment and the final study visit (approximately Day 42)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Center for Dermatology Clinical Research, Inc.
Fremont, California
Skin Sciences, PLLC
Louisville, Kentucky
J & S Studies
College Station, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Virginia Dermatology & Skin Cancer Center
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.